142 results about "Uracil" patented technology

The invention provides a uracil production strain and a construction method and application thereof.According to the strain, on an E.coli UR14 genome by means of a CRIPSR / Cas9 gene editing technology, firstly, psuG genes, preTA genes, rutA genes and upp genes are knocked out, so that decomposition of uracil is blocked; then, a uridine phosphorylase gene udp and a pyrimidine-5 '-nucleotide nucleotidase gene ppnN are subjected to overexpression, and synthesis and accumulation of uracil are synergistically enhanced; and finally, overexpression of the ribose phosphate mutase gene pgm further enhances the conversion of a by-product ribose phosphate 1-precursor 5-ribose phosphate 1-pyrophosphate and improves the carbon utilization rate, and the obtained strain has good genetic stability and high fermentation yield, can stably produce uracil, and has wide application prospects.

The present invention belongs to the technical field of genetic engineering. Provided are a single-base editor, a deaminase used therein, and the use thereof. The technical problems to be solved are to identify a naturally occurring cytosine deaminase without sequence preference, construct a base editor, and improve the efficiency and scope of base editing. In order to solve the technical problems above, a cytosine base editor is provided. The cytosine base editor is a fusion protein, wherein the fusion protein is a protein containing a cytidine deaminase, a Cas protein and a uracil-DNA glycosylase inhibitor, and the cytidine deaminase is a protein having an amino acid sequence of positions 28-164 of SEQ ID NO. 2. Further provided is the use of the fusion protein above and a biomaterial related thereto in plant single-base editing. The single-base editor can improve the efficiency of cytosine base editing and accurately mediate the base mutation of a target, and is widely applicable in the cells of maize and even other plants.

This invention discloses an ultra-low roughness chemical silver plating solution for 6G communication, comprising 2-5 g / L silver nitrate, 10-15 g / L complexing agent, 5-8 g / L nicotinic acid, 2-5 g / L reducing agent, 1-3 g / L stabilizer, 0.1-0.5 g / L surfactant, 10-30 g / L pH adjuster, 0.01-0.1 g / L grain refiner, 0.1-0.5 g / L antioxidant, and water. The invention also provides a method for its preparation. Compared with existing technologies, this invention uses specific halogenated compounds to modify uracil, improving its defects and making it less prone to ionization. The introduced groups also impart crystal plane guiding function, thereby achieving an ultra-low surface roughness of the plating layer.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

The application discloses a kind of preparation and application of multi-target small nucleic acid drug based on small activation RNA technology, and is related to the field of biotechnology.The preparation method of the multi-target small nucleic acid drug includes the following steps: (1) selecting at least two anti-disease genes according to target disease;(2) intercepting the sequence of 1000 base pairs of the promoter region upstream of the coding region of the anti-disease gene;(3) according to the promoter sequence, avoid CpG island and locate the segment of species conservation, and cut a sequence containing 19 base length as a sense strand;(4) design an antisense strand according to the sense strand, and the 19 base of the antisense strand and the sense strand are completely complementary;(5) add two deoxythymine or uracil to the 3' end of each chain.The multi-target small nucleic acid drug has good therapeutic effect on heart failure, and has strong cancer cell killing ability and inhibition ability of cancer cell migration, and has wide application prospect.

本文描述了一种用于制备测序文库的方法。所述方法可包括：在连接缓冲液中使一种或多种衔接子连接至核酸分子（例如，DNA 或 RNA）；在所述连接缓冲液中使所述核酸分子与多个珠结合；从所述连接缓冲液中分离与所述核酸分子结合的所述多个珠；将所述多个珠悬浮在包含醇的溶液中；以及使用亚硫酸氢盐反应，使所述核酸分子中的未甲基化胞嘧啶转化为尿嘧啶，以生成转化的核酸分子。

The application relates to a synthesis method of red luminescent carbon dots with a targeting diagnosis and treatment potential of hepatocellular carcinoma, which comprises the following steps: 1) adding 5-fluorouracil and indocyanine green into deionized water, uniformly mixing, and forming a uniform mixed solution; 2) heating the mixed solution obtained in the step 1) at 160-200 DEG C for 5-9 h, and cooling to room temperature; 3) filtering and dialyzing the solution obtained in the step 2), and obtaining a pure 5-FICD solution; and 4) freeze-drying the solution obtained in the step 3), and obtaining the product. The method takes anticancer drug 5-fluorouracil and photosensitizer indocyanine green as precursors, synthesizes a low-toxicity red light carbon dot through a simple hydrothermal method, improves the shortcoming that a chemotherapy drug has a large side effect, and realizes the targeted killing of hepatocellular carcinoma cells.

This invention provides a novel DNA glycosylase Bph and its application in base editing. Specifically, it provides a novel DNA glycosylase Bph and a novel base editor containing this novel DNA glycosylase. This novel base editor can achieve adenine-based base transversions. The novel DNA glycosylase of this invention can be applied to precise genome editing and has promising application prospects.

The invention provides a preparation method of trirasilil and a salt thereof, which comprises the following steps: reacting uracil with formaldehyde under an alkaline condition to obtain 5-hydroxymethyl uracil, performing chlorination, oxidation reaction and the like to obtain an intermediate 2, 4-dichloro-5-pyrimidine formaldehyde, and further preparing the trirasilil and the salt thereof from the 2, 4-dichloro-5-pyrimidine formaldehyde. According to the method, various conditions in the reaction process are optimized, so that the reaction process is stable, byproducts are few, and the yield is remarkably improved.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The invention discloses a reagent and a method for improving the tolerance of a PCR inhibitor and application, and belongs to the technical field of molecular biology. According to the invention, the thermosensitive uracil DNA glycosidase and the deoxyuridine triphosphate are combined and used as the PCR antiinhibitor to be applied to DNA amplification of a whole blood sample, and experiments prove that the composition can improve the endurance capacity of a PCR reaction system to a whole blood inhibitor, reduce the false negative rate and improve the accuracy and reliability of detection. Meanwhile, the method for carrying out PCR reaction by using the composition is simple to operate, low in cost and high in nucleic acid detection sensitivity. Therefore, the reagent and the method have a good application prospect in detection of nucleic acid extracted from a whole blood sample.

The present invention relates to a DNA base editing composition including uracil DNA glycosylase (UDG), and a DNA base editing method using same. Specifically, the present invention relates to a DNA base editing composition including a DNA binding protein, cytosine deaminase, adenine deaminase, and UDG, or polynucleotides encoding the proteins, or a DNA base editing method using same. The present invention is useful for correcting bases in nuclear DNA or organellar DNA and particularly for correcting bases in DNA of organelles such as chloroplasts or mitochondria. In the present invention, the UDG is present independently without being fused to the DNA binding protein, the cytosine deaminase, and / or the adenine deaminase.

A compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, represented by Formula (I)wherein Ring A is a ring represented by:wherein X is a single bond or the like, R2 is substituted or unsubstituted aromatic carbocyclyl or the like, R3c is substituted or unsubstituted aromatic carbocyclyl or the like, R3 is substituted or unsubstituted aromatic carbocyclyl or the like, R3a is a hydrogen atom or the like, R3b is a hydrogen atom, R8a is substituted or unsubstituted aromatic carbocyclyl or the like, and R8b is a hydrogen atom or the like,R1 is a substituted or unsubstituted aromatic heterocyclyl, m is 0 or the like, R5a is each independently a hydrogen atom or the like, R5b is each independently a hydrogen atom or the like, R6 is cyano or the like, and R7a and R7b are each independently a hydrogen atom or the like.

The construction method of the HPLC characteristic chromatogram of the coked medicated leaven medicinal material, decoction pieces and standard decoction and the determination method of the adenine content provided by the invention comprise the following steps: extracting a test raw material with 30% methanol to obtain a to-be-detected solution; determining the liquid to be detected by adopting HPLC (High Performance Liquid Chromatography) to obtain HPLC characteristic chromatograms of the coked medicated leaven medicinal material, decoction pieces and standard decoction; preparation of a reference substance solution: respectively taking uracil, adenine and 5-hydroxymethylfurfural reference substances, and dissolving the reference substances with a solvent to obtain the reference substance solution of the reference substances; the HPLC conditions are as follows: a chromatographic column is a C18 column; a mobile phase A is an acetonitrile solution, a mobile phase B is a 0.1% phosphoric acid aqueous solution, and gradient elution is carried out. According to the method, a high performance liquid chromatography method is adopted, an acetonitrile-0. 1% phosphoric acid solution is selected as a mobile phase for gradient elution, uracil, adenine and 5-hydroxymethylfurfural are taken as reference substances, and the HPLC characteristic chromatogram method for the coked medicated leaven medicinal material, decoction pieces and standard decoction is established. And more and more scientific technical means are provided for controlling the medicinal quality of the coked medicated leaven medicinal material, decoction pieces and standard decoction.

Provided is a method for effectively controlling specific weeds having resistance to herbicides. The method comprises applying one or more uracil compounds selected from a group consisting of a compound represented by formula (I):and a compound represented by formula (II):to a PPO inhibitor-resistant weed which has one or more mutations selected from a group consisting of Arg128Met mutation, Arg128Gly mutation, Arg128His mutation, Arg128Ile mutation, Arg128Lys mutation, and Gly399Ala mutation in PPO.

The invention discloses a method for directly detecting uracil-DNA glycosylase based on CbAgo and application of the method, and belongs to the field of biological detection. According to the method, a reaction system is composed of UDG, hairpin gDNA, CbAgo protein and a fluorescent probe MB. The uracil-DNA glycosylase (UDG) can specifically recognize a uracil base in a DNA chain and catalyze the base to be dissociated and released from a hairpin DNA chain, so that the hairpin structure is unstable, the shearing activity of CbAgo is activated, and a fluorescence signal of a system is enhanced. When the method is applied to detection, the content of the target UDG can be ingeniously converted into quantifiable fluorescence signals to be output, quantitative detection of the UDG is achieved, the sensitivity and the specificity are high, and a universal and sensitive detection method can be provided for UDG detection.

This invention belongs to the field of molecular biology technology, specifically involving tRF5-22-SeCTCA-1, tRF5-22-SeCTCA-1 detection reagents, kits, and their applications. This invention discovers and verifies that tRF5-22-SeCTCA-1 plays a key regulatory role in the process of 5-fluorouracil (5-FU) chemotherapy resistance in colorectal cancer, filling a gap in the research of tRNA-derived fragments (tRFs) in colorectal cancer chemotherapy resistance. It is the first tRF molecule reported to be associated with 5-FU chemotherapy resistance in colorectal cancer, providing a novel molecular target and research direction for predicting chemotherapy resistance in colorectal cancer. This invention also provides a therapeutic strategy targeting tRF5-22-SeCTCA-1 and establishes α-ketoglutarate as an independent reversal agent, providing multi-dimensional technical solutions for the precision diagnosis and treatment of colorectal cancer and the reversal of chemotherapy resistance.

A method of determining percentages of twelve blood cell subtypes in a blood specimen, includes steps of: (a) obtaining genomic DNA from the blood specimen of a human subject, (b) observing unmethylated CG loci, in the genomic DNA of the human subject, wherein said observing includes performing a bisulfate conversion process on the genomic DNA of the human subject so that cytosine residues in the genomic DNA of the human subject are transformed to uracil, while 5-methylcytosine residues in the genomic DNA of the human subject are not transformed to uracil, (c) comparing the unmethylated CG loci observed in (b) to unmethylated CG loci observed in genomic DNA collected from a reference group of human individuals and (d) correlating the unmethylated CG loci observed in (b) with the unmethylated CG loci observed in the reference group of human individuals to determine the percentage of the twelve blood cell subtypes in the blood specimen.

The present application relates to the field of pesticide herbicide, and in particular to a preparation method of 2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidine-1(2H)-yl)benzoate compound formula (I). The present application constructs a uracil ring under acidic conditions, and the intermediate prepared by the method can be used to prepare a novel efficient uracil herbicide with a structural formula of formula (I). The novel efficient uracil herbicide has stable chemical properties and better herbicidal activity, and the synthesis route is simple, and has a wide application prospect in agriculture. The present application further provides an intermediate compound used in the method, and a method for producing the intermediate compound.

The present invention relates to novel compounds of Formula (I), (I), wherein P, Q, A, B, m, n, R1 and R2 are defined as in Formula (I); which are gamma-aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which GABAB-R is involved.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The application discloses a crystallization method of an isoxazoline uracil compound, which comprises the following steps: preparing the isoxazoline uracil compound, washing an organic layer with water, and filtering; adding a certain amount of a solvent C to dissolve, and then adding a solvent B; fully mixing after heating, and crystallizing after cooling to obtain slurry, and then performing solid-liquid separation and drying to obtain a powdery solid. The application is characterized in that the mass ratio of the amount of the solvent B to the amount of the solvent C is 5:1-1:5 by optimizing the amount of the solvent C, the content of the solvent in the oily product is reduced, the saturation of the target product in the solution is improved, and the further crystallization and purification are facilitated. Moreover, the crystal form of the isoxazoline uracil compound can be changed, the isoxazoline uracil compound is changed from an oily substance into a bundle-shaped crystal form or a crystal block, and the isoxazoline uracil compound is changed from an oily substance into a powdery substance, the transfer of the production process of the isoxazoline uracil compound, the storage of the material and the usability of the product are improved, and the application range of the product is expanded.

Provided is a method for producing a ribose phosphate compound, the method comprising hydrolyzing a compound represented by general formula (3) in the presence of an acidic compound by a pressurized flow reaction, thereby producing a ribose phosphate compound represented by general formula (1). R1 represents a hydrogen atom, a hydroxy group, or OR11, and R11 represents a group represented by general formula (2). R2 and R3 each represent a hydrogen atom or a group represented by general formula (2). The two R12 each represent a hydrogen atom or an alkali metal ion. * indicates a bonding part with an oxygen atom. R5 represents an adenyl group, a guanyl group, a cytosyl group, a uracil group, or a thyminyl group.　The compounds represented by general formulae (1) and (3) each have at least one group represented by general formula (2) per molecule.

The invention belongs to the field of organic chemical synthesis, and particularly relates to a preparation method of an imino aryl compound containing uracil. The imino aryl compound containing uracil is prepared through a series of reactions. The purity of the product finally obtained through the synthesis route is 99% or above, meanwhile, high-toxicity and difficult-to-treat waste water is not generated in the process route, the used raw materials are cheap and easy to purchase, the reaction process is simple, the condition is mild, the requirement for equipment is low, the process cost is low, and industrial production is easy to carry out.

The invention discloses a compound represented by a formula I, a stereoisomer thereof, a nitrogen oxide compound or a salt thereof, and R1, R2, R3, R4, R5, R6 and G are defined in the specification. The compound provided by the invention is high in herbicidal activity, low in toxicity, small in dosage and small in environmental pollution, and has a good application prospect.

The invention specifically discloses a PreTA inhibitor and application thereof, and relates to the technical field of biological medicines. The inhibitor provided by the invention can be used for effectively inhibiting the activity of PreTA, so that the anti-tumor effect of 5-fluorouracil (5-FU) is recovered.

The invention discloses a super-long organic phosphorescent hydrogen bond organic framework material as well as a preparation method and application thereof, and belongs to the technical field of organic phosphorescent luminescent materials. Melamine and uracil are used as precursors, the ultra-long organic phosphorescent hydrogen bond organic framework material is prepared through a water-phase one-step self-assembly method, and the method is simple in process, low in cost, high in yield and environmentally friendly. The molecular formula of the ultra-long organic phosphorescent hydrogen bond organic framework is C7H12N8O3, and the ultra-long organic phosphorescent hydrogen bond organic framework is a donor-acceptor (D-A) type two-component ultra-long organic phosphorescent hydrogen bond organic framework luminescent material and belongs to a triclinic system, the space group is P-1 (2), and the cell parameters are as follows: a = 7.2826 (6), b = 8.9564 (8), c = 9.4673 (7), alpha = 66.831 (3) degrees, beta = 80.017 (3) degrees and gamma = 72.389 (3) degrees. Researches show that fluorescence and phosphorescence of the material are derived from singlet state and triplet state transition of the material respectively, and a hydrogen bond network can prolong the organic phosphorescence lifetime, so that the material has potential application value in the fields of anti-counterfeiting, biological imaging, photoelectric devices and the like.

The application provides a uridine monophosphate specific glycoside hydrolase and application thereof in biosynthetic synthesis of pseudouridine. Nmygdh The function of the gene is verified by in-vitro enzyme activity experiment Nmygdh The recombinant protein has broad-spectrum and high-efficiency catalytic activity, and can efficiently catalyze the hydrolysis of glycosidic bonds in various nucleotides, such as uridine monophosphate (UMP), guanosine monophosphate (GMP), adenosine monophosphate (AMP) and cytidine monophosphate (CMP), and the activity of uridine monophosphate is the strongest. The application uses the protein to efficiently hydrolyze uridine monophosphate to obtain two substrates of pseudouridine, i.e. uracil and 5'-phosphoribose, and realizes the atom-economical and efficient biosynthetic synthesis of pseudouridine by combining the cascade reaction of pseudouridine glycosidase EcPsuG and dephosphorylase EcYjjG.